Pure Global
NCT06328179

Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.

Clinical Study Protocol for the Treatment of Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia With KMT2A Gene Abnormalities Using VHEA（Venetoclax With Homoharringtonine，Etoposide，Cytarabine）
Huai'an First People's Hospital·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Myeloid Leukemia
Drug/Device/Intervention
Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Huai'an First People's Hospital
Location
Huai'an, China
Timeline & enrollment
Phase
N/A
Start date
May 24, 2022
End date
Dec 30, 2027
Enrollment
34 participants
Primary outcome

Overall response rate，ORR

Summary

This study is a clinical trial aimed at evaluating the efficacy and safety of the
 VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly
 diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities.
 
 This study includes the induction and consolidation phases of AML treatment.

ICD-10 classifications
Myeloid leukaemiaAcute myeloblastic leukaemia [AML]Myeloid leukaemia, unspecifiedAcute myelomonocytic leukaemiaAcute myeloid leukaemia with 11q23-abnormality
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06328179
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06328179 through Pure Global AI's free database. This phase not specified trial is sponsored by Huai'an First People's Hospital and is currently Recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 34 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.